Moderna Outlines Growth Plans at Analyst Day
Moderna highlighted intismeran and cancer antigen therapies as opportunities for its oncology franchise, and discussed commercial and manufacturing readiness for intismeran after positive Phase 3 results in adjuvant melanoma.